Molecular and cellular effects of Auger emitters: 2008-2011

International Journal of Radiation Biology

Volumn 88, Issue 12, 2012, Pages 864-870

  Yasui, Linda S ^a  

^a NORTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

Auger emitters; Cytotoxicity; Increasing accumulation of Auger emitters; Targeting Auger emitters

Indexed keywords

5 RADIOIODO 2' DEOXYURIDINE; ANDROGEN; ANDROGEN RECEPTOR; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CELL SURFACE RECEPTOR; DAUNORUBICIN; DNA; ELLIPTICINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; GEFITINIB; HISTONE H2AX; INDIUM 111; IODINE 125; L 788123; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; MORPHOLINO OLIGONUCLEOTIDE; NANOPARTICLE; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STREPTAVIDIN; TECHNETIUM 99M; TRANSACTIVATOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AUGER ELECTRON SPECTROSCOPY; AUGER ELECTRON THERAPY; AUGER EMITTER; BREAST CANCER; CARCINOMATOUS PERITONITIS; CELLULAR DISTRIBUTION; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ELECTRON; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; ISOTOPE LABELING; MESOTHELIOMA; MOLECULAR RADIOTHERAPY; NONHUMAN; OVARY CANCER; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; TARGET CELL; TARGETING AUGER EMITTER; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CHEMISTRY; HUMANS; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASMS; PHYSICAL PROCESSES;

EID: 84870490971     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2012.702296     Document Type: Conference Paper

References (43)

1. Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, Vallis KA. 2007. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron-emitting radiopharmaceutical 111 In-DTPA-human epidermal growth factor. The Journal of Nuclear Medicine 48 : 1562-1570.
2. Baranowska-Kortylewicz J. 2011. Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors. Immunotherapy 3: 491-494.
3. Boudousq V, Ricaud S, Garambois V, Bascoul-Mollevi C, Boutaleb S, Busson M, Quenet F, Golombo P-E, Bardies M, Kotzki P-O, Navarro- Teulon I, Pelegrin A, Pouget J-P. 2010. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of non-internalizing 125 I-labeled monoclonal antiodies. The Journal of Nuclear Medicine 51 : 1748-1755.
4. Cai Z, Pignol J-P, Chan C, Reilly RM. 2010. Cellular dosimetry of 111 In using Monte Carlo N-particle computer code: Comparison with analytic methods and correlation with in vitro cytotoxicity. The Journal of Nuclear Medicine 51 : 462-470.
5. Cai Z, Vallis KA, Reilly RM. 2009. Computational analysis of the number, area and density of H2AX foci in breast cancer cells exposed to 111 In-DTPA-hEGF or rays using Image J software. International Journal of Radiation Biology 85 : 262-271.
6. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. 2008. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111 In-DTPA-hEGF. The Journal of Nuclear Medicine 49 : 1353-1361.
7. Chrastina A, Schnitzer JA. 2010. Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging. International Journal of Nanomedicine 5 : 653-659.
8. Cornelissen B, Kersemans V, Darbar S, Thompson J, Shah K, Sleeth K, Hill MA, Vallis KA. 2011a. Imaging DNA damage in vivo using H2AXtargeted immunoconjugates. Cancer Research 71: 4539-4549.
9. Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly RM, Vallis KA. 2011b. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance 111 In-DTPA-hEGF Auger electron radiation therapy. The Journal of Nuclear Medicine 52 : 776-783.
10. Cornelissen B, Vallis KA. 2010. Targeting the nucleus: An overview of Auger electron radionuclide therapy. Current Drug Discovery Technologies 7 : 263-279.
11. Costantini DL, Villani DF, Vallis KA, Reilly RM. 2010a. Methotrexate, paclitaxel, and doxorubinin, radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting 111 In-NLSTrastuzumab. The Journal of Nuclear Medicine 51 : 477-483.
12. Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. 2010b. Antitumor effects and normal tissue toxicity of 111 In-nuclear localization sequence-Trastuzumab in athymic mice bearing HERpositive human breast cancer xenografts. The Journal of Nuclear Medicine 51 : 1084-1091.
13. Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. 2008. Tratuzumab-resistant breast cancer cells remain sensitive to the Auger electron-emitting radiotherapeutic agent 111 In-NLSTratuzumab and are radiosensitized by methotrexate. The Journal of Nuclear Medicine 49 : 1498-1505.
14. Ertl HH, Feinendegen LE, Heiniger HJ. 1970. Iodine-125, a tracer in cell biology: Physical proterties and biological aspects. Physics Medicine Biology 15 : 447-456.
15. Feinendegen LE, Ertl HH, Bond VP. 1971. In: Ebert H, editor. Proceedings of the symposium on biological aspects on radiation quality. Vienna: IAEA. pp 419-430.
16. Fondell A, Edwards S, Ickenstein LM, Sjoberg S, Carlsson J, Gedda L. 2010. Nuclisome: A novel concept for radionuclide therapy using targeting liposomes. European Journal Nuclear Medicine Molecular Imaging 37: 114-123.
17. Hanahan D, Weinberg RA. 2000. Hallmarks of cancer. Cell 100: 57-70.
18. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144 : 646-674.
19. Hofer KG, Warters RL. 1986. Cell lethality after selective irradiation of the DNA replication fork. Radiation Environment Biophysics 24: 161-174.
20. Hofer KG, Prensky W, Hughes WL. 1969. Death and metastatic distribution of tumor cells in mice monitored with 125I-iododeoxyuridine. Journal of the National Cancer Institute 43 : 763-773.
21. Hofer KG, Hughes WL. 1971. Radiotoxicity of intranuclear tritium, 125 Iodine and 131 Iodine. Radiation Research 47: 94-109.
22. Kassis A. 2011. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiation Protection Dosimetry 143: 2-4.
23. Kassis AI, Kirichian AM, Wang K, Semnani ES, Adelstein SJ. 2004. Therapeutic potential of 5-[ 125 I]iodo-2'-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. International Journal of Radiation Biology 80: 941-946.
24. Kersemans V, Cornelissen B, Minden MD, Brandwein J, Reilly RM. 2008. Drug resistant AML cells and primary AML specimens are killed by 111 In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. The Journal of Nuclear Medicine 49 : 1546-1554.
25. Kortylewicz ZP, Nearman J, Baranowska-Kortylewicz J. 2009. Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'- deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: Synthesis and biological evaluation. Journal of Medicinal Chemistry 52 : 5124-5143.
26. Kulberg EB, Wei Q, Capala J, Giusti V, Malmstrom PU, Gedda L. 2005. EFG-receptor targeted liposomes with boronated acridine: Growth inhibition of cultured glioma cells after neutron irradiation. International Journal of Radiation Biology 81 : 621-629.
27. Lehnert S, Li Y, Bump E, Riddoch B, Chenite A, Shive A. 2011. 125 Iiododeoxuridine for the treatment of a brain tumor model: Selection of conditions for optimal effectiveness. The Open Nuclear Medicine Journal 3 : 19-24.
28. Liu X, Wang Y, Nakamura K, Kawauchi S, Akalin A, Cheng D, Chen L. 2009. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111 In. The Journal of Nuclear Medicine 50 : 582-590.
29. Lo HW, Ali-Sayed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. 2006. Nuclear-cytoplasmic transport of EGFR involved receptor endocytosis, importin beta1 and CRM1. Journal of Cell Biochemistry 98 : 1570-1583.
30. Meijer AJ. 2008. Amino acid regulation of autophagosome formation. In: Deretic V, editor. Methods in molecular biology. Hatfield, Hertfordshire, UK: Humana Press. Vol. 445 : Autophagosomes and phagosome.
31. Mettivier G, Montesi MC, Curion AS, Lauria A, Marotta M, Russo, P. 2010. High resolution 125 I pinhole SPECT imaging of the mouse thyroid with the MediSPECT small animal CDTe scanner. IEEE Transactions on Nuclear Science 57 : 1029-1037.
32. Morgenroth A, Deisenhofer S, Glatting G, Kunkel F-HG, Dinger C, Zlatopskiy B, Vogg ATJ, Kull T, Reske SN. 2008. Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125 I]Iodo-4'-Thio-2'-Deoxyuridine. Clinical Cancer Research 14: 7311-7319.
33. Ndlebe T, Panyutin I, Neumann R. 2010. Analysis of the contribution of charge transport in iodine-125. Radiation Research 173: 98-109.
34. Pitula S, Wiebke J. 2004. Quantum chemical investigations on the Auger process induced fragmentation of organic compounds and its significance to DNA irradiation damage. Beitr a ge zumWissenschaftlichen Rechnen Ergebnisse des Gaststudentenprogramms 2004 des John von Neumann-Instituts fur Computing. Nov. 2004.
35. Pouget J-P, Santoro L, Raymond L, Chouin N, Bardies M, Bascoul-Mollevi C, Huguet H, Azria D, Kotzki P-O, Pelegrin M, Vivers E, Pelegrin A. 2008. Cell membrane is a more sensitive target than cytoplasm to denseionization produced by Auger electrons. Radiation Research 170: 192-200.
36. Rajon R, Bolch RE, Howell RW. 2011. Lognormal distribution of cellular uptake of radioativity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaff olds. The Journal of Nuclear Medicine 52 : 926-933.
37. Reilly RM, Chen P, Wand J, Scollard D, Cameron R, Vallis KA. 2006. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111 In-DTPA-human epidermal growth factor: An Auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. Th e Journal of Nuclear Medicine 47 : 1023-1031.
38. Sak A, Stuschke, M. 2010. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Seminars in Radiation Oncology 20 : 223-231.
39. Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki P-O, Pelegrin M, Navarro-Teulon I, Pelegrin A, Pouget J-P. 2009. Noninternalizing monoclonal antibodies are suitable candidates for 125 I radioimmunotherapy of small-volume peritoneal carcinomatosis. The Journal of Nuclear Medicine 50 : 2033-2041.
40. Sedlacek O, Hruby M, Studenovsky M, Kucka J, Vetvicka D, Kovar L, Rihova B, Ulbrich K. 2011. Ellipticine-aimed polymer-conjugated auger electron emitter: Multistage organelle targeting approach. Bioconjugate Chemistry 22 : 1194-1201.
41. Weinberg RA. 2007. Th e biology of cancer. New York: Garland Sciences, Taylor and Francis Group LLC.
42. Yasui L, Hofer KG, Warters RL. 1985. Inhomogeneity of the nucleus to 125 IUdR cytotoxicity. Radiation Research 102: 106-118.
43. Zanzonico P. 2011. Cell-level dosimetry and biologic response modeling of heterogeneously distributed radionuclides: A step forward. The Journal of Nuclear Medicine 52: 845-847.